Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Pain. 2014 Mar 21;155(7):1229–1237. doi: 10.1016/j.pain.2014.03.012

Fig. 2.

Fig. 2

Spinal effects of exogenous TLQP-21 peptide. A, Intrathecal injection of TLQP-21 induced dose-dependent thermal hyperalgesia in the warm water immersion tail withdrawal test. B–D, The p38 MAPK inhibitor SB202190 (B), the cyclooxygenase (COX) inhibitor indomethacin (C), and 5-lipoxygenase inhibitor AA861 (D) attenuated thermal hyperalgesia evoked by TLQP2-1 (3 nmol) in a dose-dependent manner (measured 90 min after i.t. injection of TLQP-21; p < 0.05, One-Way ANOVA, Bonferroni post-hoc test). A–D, n = 3–6 mice per group.